Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Adaptive Biotechnologies Corp(ADPT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ADPT
11/03/2026: ADPT (2-star) is currently NOT-A-BUY. Pass it for now.
Adaptive Biotechnologies is a life sciences company specializing in mapping the human adaptive immune system for diagnostics and drug discovery. Its core strength lies in the clonoSEQ assay, which has a leading position in minimal residual disease monitoring for blood cancers. The primary investment story centers on expanding this diagnostic footprint and leveraging immune data for lucrative biopharma collaborations. However, the company faces risks from high cash burn, evolving reimbursement policies, and competition from large, well-funded diagnostic firms. It may suit growth-oriented investors who can tolerate volatility, while monitoring developments in clinical adoption and path-to-profitability remains crucial for long-term assessment.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company targets high-growth markets in oncology but faces significant execution risks and cash burn. |
| Momentum investor | Weak fit | The stock often lacks consistent positive technical momentum required for short-term trading strategies. |
| Value investor | Weak fit | The lack of consistent profitability makes it an unsuitable candidate for traditional value metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on growth reinvestment. |
| Low-risk investor | Weak fit | High volatility associated with clinical-stage and growth-stage biotech makes this unsuitable for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often experience sharp price movements based on clinical data or earnings results. |
| Valuation risk | Medium / high | Investors must pay for future growth that is not yet backed by GAAP profitability. |
| Competition risk (Oncology diagnostics) | High | Established players with greater scale can impact pricing and market share in MRD testing. |
| Business quality | Medium | While the platform technology is robust, the commercial path to consistent margins is still maturing. |
| Dividend income | Low / none | The company does not provide income to shareholders. |
| Execution risk | Medium / high | The company must successfully scale its sales force and diagnostic test adoption to achieve self-sustainment. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -2.73% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/03/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.00B USD | Price to earnings Ratio - | 1Y Target Price 30.21 |
Price to earnings Ratio - | 1Y Target Price 30.21 | ||
Volume (30-day avg) 2.2M shares | Beta 2.15 | 52 Weeks Range 12.00 - 30.74 | Updated Date 11/03/2026 |
52 Weeks Range 12.00 - 30.74 | Updated Date 11/03/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.41 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Diagnostics | Revenue generated primarily from the clonoSEQ assay for clinical use. | The company makes money when doctors use their tests to monitor cancer patients. |
| Biopharmaceutical Collaborations | Fees and milestones from partnerships using the immune medicine platform for drug discovery. | The company earns income by helping drug developers find better treatments using immune system data. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4.32B | Price to Sales(TTM) 12.98 |
Enterprise Value 4.32B | Price to Sales(TTM) 12.98 | ||
Enterprise Value to Revenue 14.02 | Enterprise Value to EBITDA -1 | Shares Outstanding 159.60M | Shares Floating 125.49M |
Shares Outstanding 159.60M | Shares Floating 125.49M | ||
Percent Insiders 1.29 | Percent Institutions 101.01 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.